Announced details
Duchenne muscular dystrophy (DMD) treatment, gene therapy
Counterparty to the joint research and licensing agreement. Exegenesis Bio will provide the AAV capsid technology, while Modalis will provide the CRISPR-GNDM® payload and development expertise.
Headquarters: Pennsylvania, United States. Representative Director and CEO: Zhenhua Wu. A biotechnology company focused on gene therapy and oligonucleotide medicines. It conducts research and development and business development using AAV vectors and related technologies.
Exegenesis Bio: Pennsylvania, United States. Modalis: research and development facilities in Massachusetts, United States.
The impact on results for the current fiscal year will be minor, and no revision to the earnings forecast has been made at this time.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | MDL-201, EMC181, CRISPR-GNDM® |
| Counterparty | Exegenesis Bio |
| Counterparty overview | Headquarters: Pennsylvania, United States. Representative Director and CEO: Zhenhua Wu. A biotechnology company focused on gene therapy and oligonucleotide medicines. It conducts research and development and business development using AAV vectors and related technologies. |
| Relationship with the Company | Counterparty to the joint research and licensing agreement. Exegenesis Bio will provide the AAV capsid technology, while Modalis will provide the CRISPR-GNDM® payload and development expertise. |
| Contract Date | 11 September 2026 (joint research and licensing agreement signed; the agreement takes effect on 14 September 2026) |
| Launch date | 14 September 2026 (scheduled contract effective date) |
| Applicable area | Duchenne muscular dystrophy (DMD) treatment, gene therapy |
| Location | Exegenesis Bio: Pennsylvania, United States. Modalis: research and development facilities in Massachusetts, United States. |
| Impact on Business Performance | The impact on results for the current fiscal year will be minor, and no revision to the earnings forecast has been made at this time. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To combine Exegenesis Bio's AAV capsid, which has muscle-targeting and liver-detargeting properties, with Modalis's CRISPR-GNDM® payload, with the aim of improving delivery to muscle tissue, reducing exposure to non-target tissues, and accelerating the nonclinical and clinical development of MDL-201.